Genmab — November 2020

[Helge_LarsenPI-redaktør]

Følg NBI her. Der er ikke storudsalg af Pharma i US. https://indexes.nasdaqomx.com/Index/Overview/NBI

[DevOp]

Shoot me, hvis jeg har overset det tidligere, men abstract for gen1046 https://jitc.bmj.com/content/8/Suppl_3/A437 angiver, at der faktisk bliver præsenteret opdaterede data, og at 65,6% (40/61) pts opnåede stable disease eller partial response. Fordelt over både triple-negative breast cancer, ovarian cancer, and immune checkpoint inhibitor (ICI)–pretreat
ed NSCLC

[DevOp]

Det er altså svært at være utilfreds med, selv om det har været en møgdag på kontoret ellers...

[Bulder]

Jo, det har vi vidst siden E L hackede SITC for længe siden. Vi får opdaterede data på onsdag med posteren.

[DevOp]

u r so right, det havde jeg glemt alt om. Så bliver det svært at vente til onsdag.

[E_L]

haha, i don't have any hacking skills -unfortunately- but I think it is a great idea! @Helge; can you hire a hacker please

[Helge_LarsenPI-redaktør]

E L ..One more?

[E_L]

[GeorgeBest]

Genmab presented dose escalation data for its DuoBody-PD-L1x4-1BB in 61 patients with advanced solid tumours at SITC today with six months of follow up. Early data is encouraging with an 11-33% ORR across TNBC https://twitter.com/semodough/status/1325984229063192576?s=21

[Helge_LarsenPI-redaktør]

God morgen.

[Helge_LarsenPI-redaktør]

Asien: Generelle stigninger på positivt vaccinehåb - NY
https://www.proinvestor.com/investornyt/669448/asien-generelle-stigninger-pa-positivt-vaccinehab-ny

[Helge_LarsenPI-redaktør]

Tirsdagens aviser med Tryg, Carlsberg og https://www.proinvestor.com/investornyt/669447/tirsdagens-aviser-med-tryg-
carlsberg-og-nnit

[Helge_LarsenPI-redaktør]

Aktier/tendens: Ørsted kan tage fokus efter løftet anbefalinghttps://www.proinvestor.com/investornyt/669456/aktier-tendens-orsted-

[E_L]

BioNTech SEC filings GEN1046
; you can choose if you want ot download it or just view it in your browser by clicking html https://investors.biontech.de/sec-filings/sec-filing/6-k/0001564590-20-052594

[E_L]

cut off date Aug31

[E_L]

Data cut-off for Efficacy September 29 I see

[E_L]

Disease control was achieved in 65.6% of patients, including
partial responses in triple-negative breast cancer (n=1), ovarian
cancer (n=1), and ICI-pretreated NSCLC (n=2).

[E_L]

Of six patients with NSCLC, all of whom
had received prior immune checkpoint
inhibitor (ICI) therapy, two achieved
unconfirmed PR, two maintained SD, and
two experienced progressive disease

[E_L]

Expansion cohort
● As of October 12, 2020, 24 patients were enrolled in expansion cohort 1, which includes patients with
NSCLC with progression on or after ICI therapy (Figure 8).
– 12 patients had post-baseline scans; six patients continued treatment with GEN1046, six patients
discontinued.
– Preliminary efficacy in 12 patients who could be objectively assessed showed two patients who
achieved confirmed PR, one with unconfirmed PR, and four patients with SD.

[E_L]

So it seems they start with NSCLC in the expansian cohorts? Note there where only 6 patients in the escalation cohort, they already put 24 in the expansian as of Oct 12